Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats

Life Sciences

Volumn 147, Issue , 2016, Pages 125-131

  Takakura, Shoji ^a   Toyoshi, Tohru ^b   Hayashizaki, Yuka ^a   Takasu, Toshiyuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b Nihon Bioresearch Inc   (Japan)

Author keywords

Cataract; Diabetic microvascular complications; Ipragliflozin L proline (PubChem CID: 57339444); Nephropathy; Neuropathy; Retinopathy; Sodium dependent glucose cotransporter 2; Type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; IPRAGLIFLOZIN; NITROGEN; TRIACYLGLYCEROL; UREA; ANTIDIABETIC AGENT; GLUCOSIDE; SGLT2 PROTEIN, RAT; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACTOGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFECT; ELECTRORETINOGRAM; FOOD INTAKE; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; MALE; MOTOR NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSCILLATORY POTENTIAL; RAT; SPONTANEOUSLY DIABETIC TORII RAT; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URINALYSIS; WEIGHT CHANGE; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; HYPERGLYCEMIA; SPRAGUE DAWLEY RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; GLUCOSIDES; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84957586606     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.01.042     Document Type: Article

References (40)

1. M.J. Fowler Microvascular and macrovascular complications of diabetes Clin. Diab. 26 2 2008 77 82
2. W.T. Cade Diabetes-related microvascular and macrovascular diseases in the physical therapy setting Phys. Ther. 88 11 2008 1322 1335
3. C. Bradley, and et al. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL Qual. Life Res. 8 1-2 1999 79 91
4. K. Vithian, and S. Hurel Microvascular complications: pathophysiology and management Clin. Med. 10 5 2010 505 509
5. A.J. Boulton, and et al. Diabetic neuropathies: a statement by the American Diabetes Association Diabetes Care 28 4 2005 956 962
6. M.A. Nauck Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Drug Des. Devel. Ther. 8 2014 1335 1380
7. V. Vallon, and et al. SGLT2 mediates glucose reabsorption in the early proximal tubule J. Am. Soc. Nephrol. 22 1 2011 104 112
8. Y.J. Lee, and H.J. Han Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells Kidney Int. Suppl. 72 2007 S27 S35
9. E.C. Chao, and R.R. Henry SGLT2 inhibition-a novel strategy for diabetes treatment Nat. Rev. Drug Discov. 9 7 2010 551 559
10. M.A. Abdul-Ghani, and et al. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes Endocr. Rev. 32 4 2011 515 531
11. N. Kojima, and et al. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats J. Pharmacol. Exp. Ther. 345 3 2013 464 472
12. F. Gembardt, and et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension Am. J. Physiol. Renal Physiol. 307 3 2014 F317 F325
13. T. Nagata, and et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice Br. J. Pharmacol. 170 3 2013 519 531
14. N. Terami, and et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice PLoS One 9 6 2014 e100777
15. K. Ueta, and et al. Long-term treatment with the Na +-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats Life Sci. 76 23 2005 2655 2668
16. T. Masuyama, and et al. Chronological characterization of diabetes development in male Spontaneously Diabetic Torii rats Biochem. Biophys. Res. Commun. 314 3 2004 870 877
17. T. Masuyama, and et al. A novel model of obesity-related diabetes: introgression of the Lepr(fa) allele of the Zucker fatty rat into nonobese Spontaneously Diabetic Torii (SDT) rats Exp. Anim. 54 1 2005 13 20
18. K. Matsui, and et al. Diabetes-associated complications in Spontaneously Diabetic Torii fatty rats Exp. Anim. 57 2 2008 111 121
19. T. Yamaguchi, and et al. Diabetic peripheral neuropathy in Spontaneously Diabetic Torii-Lepr(fa) (SDT fatty) rats J. Vet. Med. Sci. 74 12 2012 1669 1673
20. M. Imamura, and et al. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus Bioorg. Med. Chem. 20 10 2012 3263 3279
21. A. Tahara, and et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo Naunyn Schmiedeberg's Arch. Pharmacol. 385 4 2012 423 436
22. T. Takasu, and et al. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice Clin. Exp. Pharmacol. Physiol. 42 1 2015 87 93
23. V.A. Fonseca, and et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus J. Diabetes Complicat. 27 3 2013 268 273
24. A. Kashiwagi, and et al. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus J. Diabetes. Investig. 5 4 2014 382 391
25. M. Yokono, and et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats Eur. J. Pharmacol. 727 2014 66 74
26. S. Ao, and et al. Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract Invest. Ophthalmol. Vis. Sci. 32 12 1991 3078 3083
27. H. Nakamura, and et al. Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models Eur. J. Pharmacol. 512 2-3 2005 239 246
28. A.K. Sharma, and P.K. Thomas Peripheral nerve structure and function in experimental diabetes J. Neurol. Sci. 23 1 1974 1 15
29. I. Idris, and R. Donnelly Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug Diabetes Obes. Metab. 11 2 2009 79 88
30. E. Ferrannini, and et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients J. Clin. Invest. 124 2 2014 499 508
31. C. Biallosterski, and et al. Decreased optical coherence tomography-measured pericentral retinal thickness in patients with diabetes mellitus type 1 with minimal diabetic retinopathy Br. J. Ophthalmol. 91 9 2007 1135 1138
32. H.W. van Dijk, and et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy Invest. Ophthalmol. Vis. Sci. 50 7 2009 3404 3409
33. R. Tzekov, and G.B. Arden The electroretinogram in diabetic retinopathy Surv. Ophthalmol. 44 1 1999 53 60
34. Y. Katsuda, and et al. Diabetic complications in obese type 2 diabetic rat models Exp. Anim. 63 2 2014 121 132
35. N.E. Cameron, and M.A. Cotter Metabolic and vascular factors in the pathogenesis of diabetic neuropathy Diabetes 46 Suppl. 2 1997 S31 S37
36. T.W. Tervaert, and et al. Pathologic classification of diabetic nephropathy J. Am. Soc. Nephrol. 21 4 2010 556 563
37. V. Vallon, and et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice Am. J. Physiol. Renal Physiol. 306 2 2014 F194 F204
38. S.L. Konzem, and et al. Controlling hypertension in patients with diabetes Am. Fam. Physician 66 7 2002 1209 1214
39. Y. Ishii, and et al. Evaluation of blood pressure in Spontaneously Diabetic Torii-Lepr(fa) rats Exp. Anim. 59 4 2010 525 529
40. W.L. Baker, and et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis J. Am. Soc. Hypertens. 8 4 2014 262 275 e9